Breaking News, Financial News

Financial Report: Alexion

Revenues up 48% in the quarter

Alexion
 
2Q Revenues:  $274.7 million (+48%)
 
2Q Earnings: $36.3 million (+5%)
 
YTD Revenues: $519.5 million (+48%)
 
YTD Earnings: $81.7 million (+33%)
 
Comments: Revenues were driven by Soliris, which added the indication of atypical hemolytic uremic syndrome late last year. R&D expenses rose 70% to $60 million as the company advanced several drugs in its pipeline.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters